During a recent visit to Japan ahead of the upcoming G7 Summit, members of the Biopharmaceutical CEO Roundtable (BCR) made another call on behalf of the research-based biopharma industry for the country’s government to set up a new strategic reform discussion on health and medicine issues.
Global CEO Grouping Lays Out Japan, Wider Priorities Ahead Of G7 Meeting
UHC, Access, Pricing In Spotlight
The Biopharmaceutical CEO Roundtable has added a chorus of C-suite voices to ongoing calls for Japan reform discussions, while also flagging key global health agenda items for the upcoming G7 meeting in the country.
More from Japan
• By
Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.
• By
Japan adds four new pediatric vaccines, including for MMRV and norovirus, to a list of priority vaccines eligible for assistance in regulatory processing.
• By
Japan recommends eight new drugs for approval, including two for cardiomyopathy, and will also raise prices for multiple products, including Enhertu, on 1 April.
• By
A plan to reduce benefits under Japan's financial safety net for patients contributing to the costs of their long-term medical care is being reconsidered by the government following protests from patient and doctor groups.
More from Asia
• By
A new annual report from China's CDE shows a rise in overall product approvals but a fall in the transition rate for conditional to full approvals, possibly signalling more stringent requirements.
• By
Japan adds four new pediatric vaccines, including for MMRV and norovirus, to a list of priority vaccines eligible for assistance in regulatory processing.
• By
While CMC glitches linger over a US NDA for Elevar/Hengrui’s novel liver cancer combination following a second complete response letter, the separate issue of underrepresentation of US patients in multiregional trials is looming large after new FDA draft guidance last year.